MGTX

Insider Trades

Name	Value	Action	Price	Current Price
Forbes AlexandriaDirector, Officer: PRESIDENT & CEO $569k62k shares SellMay 19, 2026 $9.17 --
Giroux RichardCFO & COO $572k56k shares SellApr 21, 2026 $10.22 --
Naylor StuartCHIEF DEV. OFFICER $259k27.7k shares SellApr 7, 2026 $9.36 --
Forbes AlexandriaDirector, Officer: PRESIDENT & CEO $459k62k shares SellMar 24, 2026 $7.41 --
Giroux RichardCFO & COO $213k24k shares SellOct 21, 2025 $8.87 --
Forbes AlexandriaDirector, Officer: PRESIDENT & CEO $399k47.5k shares SellOct 7, 2025 $8.39 --

News

seekingalpha.comMeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 5

seekingalpha.comMeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 15

globenewswire.comMeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 14

zacks.comMeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 14

globenewswire.comMeiraGTx Reports First Quarter 2026 Financial and Operational Resultsglobenewswire.comMay 14

Trade MGTX

About MeiraGTx Holdings plc

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

CEO: Alexandria Forbes
IPO Date: Jun 8, 2018

Market Data

Open: $10.62
High: $11.75
Low: $10.61
Volume: 2.2M
Avg Volume: 881.3K
52W High: $11.85
52W Low: $6.07

Valuation

Market Cap: $1.0B
Enterprise Value: $1.1B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-50M
Revenue: $81M
Net Income: $-114M
Cash: $66M
Debt: $89M

Events

EarningsAug 13

EPS est. -0.31143